Moderna, Inc. (MRNA) saw its stock plummet by 5.06% in pre-market trading on Thursday, following reports that the Trump administration is considering withdrawing funding for the company's $590 million bird flu vaccine contract.
The contract, awarded by the Biden administration in its final days, aimed to advance the development of Moderna's messenger RNA (mRNA)-based bird flu vaccine. However, the new Trump administration is reevaluating the deal as part of a broader push to scrutinize spending on mRNA vaccines, a technology widely used during the COVID-19 pandemic.
According to reports, the potential loss of this significant funding could deal a blow to Moderna's future revenue and growth prospects, as the bird flu contract was seen as a significant part of its pipeline. Investors are likely concerned that without this funding, Moderna may struggle to advance the development of the vaccine, hampering its ability to diversify its revenue streams beyond COVID-19 vaccines.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。